Santen expects to begin with scientific trials in early 2011. Obtained Orphan Medication Designation from the FDA for PRX-8066, a selective serotonin 2B receptor antagonist, in Phase II advancement for pulmonary arterial hypertension Received two grants totaling nearly $0.5 million for research and development efforts related to Viibryd and Stedivaze Reported a cash burn for the quarter of $4.7 million, including $6.0 million linked to a portion of the cash proceeds from the sale of the business’s genetic testing business, $1.5 million from the release of funds held in escrow from a earlier transaction, and other items totaling around $1.0 million Related StoriesTesting amniotic fluid could lead doctors to make delivery preparing decisions for preterm birthsGenetic reduced amount of AMPK enzyme can prevent or delay hearing lossUCSF-led researchers map out melanoma's genetic trajectoriesCommenting on the business’s third quarter financial outcomes, Mr.‘Rates of weight problems have continuing to climb within the last 10 years across all age ranges. Surgery for morbid obesity happens to be the most efficient treatment.’ The achievement of bariatric medical procedures has expanded the treating morbid weight problems and its own conditions for individual populations that hadn’t previously been offered. Medicare has begun covering bariatric medical procedures although significant death prices have already been reported in Medicare individuals undergoing medical procedures. Peter T. Hallowell, M.D., and co-workers of University Hospitals Case INFIRMARY and Case Western Reserve University School of Medication, Cleveland, reviewed the situations of 892 sufferers who experienced gastric bypass operation from 1998 to 2006.